Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler

Simple Summary In breast cancer, there is a high degree of variability in tumors and the surrounding tissue called the tumor microenvironment (TME). To better understand tumor biology and metastasis, as well as to predict response to cancer treatments or the course of the disease, it is important to characterize molecular diversity in the breast TME. The GeoMx Digital Spatial Profiler (DSP) enables researchers to spatially analyze proteins and RNA transcripts in tumors and surrounding tissues from patients or preclinical models. Using the GeoMx DSP, protein expression and RNA transcripts in the distinct regions of a tumor can be quantified up to and including the whole transcriptome level. Herein, the GeoMx Breast Cancer Consortium presents best practices for GeoMx spatial profiling of tumors to promote the collection of high-quality data, optimization of data analysis and integration of datasets to accelerate biomarker discovery. These best practices can also be applied to any tumor type to provide information about the tumor and the TME. Abstract Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication. High-plex spatial profiling of tumors enables characterization of heterogeneity in the breast TME, which can holistically illuminate the biology of tumor growth, dissemination and, ultimately, response to therapy. The GeoMx Digital Spatial Profiler (DSP) enables researchers to spatially resolve and quantify proteins and RNA transcripts from tissue sections. The platform is compatible with both formalin-fixed paraffin-embedded and frozen tissues. RNA profiling was developed at the whole transcriptome level for human and mouse samples and protein profiling of 100-plex for human samples. Tissue can be optically segmented for analysis of regions of interest or cell populations to study biology-directed tissue characterization. The GeoMx Breast Cancer Consortium (GBCC) is composed of breast cancer researchers who are developing innovative approaches for spatial profiling to accelerate biomarker discovery. Here, the GBCC presents best practices for GeoMx profiling to promote the collection of high-quality data, optimization of data analysis and integration of datasets to advance collaboration and meta-analyses. Although the capabilities of the platform are presented in the context of breast cancer research, they can be generalized to a variety of other tumor types that are characterized by high heterogeneity.

[1]  A. Regev,et al.  The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. , 2021, Cancer cell.

[2]  Krishna R. Kalari,et al.  Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer , 2021, Clinical Cancer Research.

[3]  S. Yao,et al.  Multiplexed digital spatial profiling of invasive breast tumors from Black and White women , 2021, Molecular oncology.

[4]  G. Curigliano,et al.  Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. , 2021, European journal of cancer.

[5]  P. Nelson,et al.  Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling , 2021, Nature communications.

[6]  R. Greil,et al.  PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial , 2021, The British journal of surgery.

[7]  J. Cuzick,et al.  Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna® , 2021, NPJ breast cancer.

[8]  Nicolò Riggi,et al.  Non-genetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. , 2021, Cancer discovery.

[9]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[10]  J. Merchant,et al.  Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma , 2020, Cancers.

[11]  Nina M. Muñoz,et al.  Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma , 2020, Communications biology.

[12]  Tong Li,et al.  Comprehensive mapping of tissue cell architecture via integrated single cell and spatial transcriptomics , 2020, bioRxiv.

[13]  G. Viale,et al.  Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses , 2020, Breast cancer research : BCR.

[14]  Alina M. Hamilton,et al.  Protein-based immune profiles of basal-like vs. luminal breast cancers , 2020, Laboratory Investigation.

[15]  P. Fasching,et al.  Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients , 2020, Clinical Cancer Research.

[16]  Jennifer L. Caswell-Jin,et al.  Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response , 2020, Nature Cancer.

[17]  Justine Jia Wen Seow,et al.  Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma , 2020, Cell.

[18]  J. Yun,et al.  Immune parameters associated with survival in metaplastic breast cancer , 2020, Breast Cancer Research.

[19]  P. Danaher,et al.  Advances in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene expression data , 2020, bioRxiv.

[20]  C. Perou,et al.  Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer , 2020, Clinical Cancer Research.

[21]  D. Richard,et al.  High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC) , 2020, medRxiv.

[22]  Peter T. Simpson,et al.  Digital spatial profiling application in breast cancer: a user’s perspective , 2020, Virchows Archiv.

[23]  Andrew H. Beck,et al.  Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group , 2020, npj Breast Cancer.

[24]  G. Mills,et al.  Multiplex digital spatial profiling of proteins and RNA in fixed tissue , 2020, Nature Biotechnology.

[25]  K. Varley,et al.  Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis , 2020, Scientific Reports.

[26]  R. Herbst,et al.  Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling , 2020, Clinical Cancer Research.

[27]  Y. Haupt,et al.  High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot , 2020, Journal for immunotherapy of cancer.

[28]  A. Gown,et al.  The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice , 2020, The Journal of pathology.

[29]  D. Germain,et al.  Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments? , 2020, Cancer Research.

[30]  Catherine J. Wu,et al.  Directing Traffic: How to Effectively Drive T Cells into Tumors. , 2020, Cancer discovery.

[31]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[32]  A. Gure,et al.  A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer , 2020, Journal of Cancer.

[33]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[34]  Shila Ghazanfar,et al.  Toward a Common Coordinate Framework for the Human Body , 2019, Cell.

[35]  Tonje G. Lien,et al.  An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment , 2019, Nature Communications.

[36]  M. Lucia,et al.  Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients , 2019, Journal of Immunotherapy for Cancer.

[37]  D. Cescon,et al.  If we build it they will come: targeting the immune response to breast cancer , 2019, npj Breast Cancer.

[38]  C. Sotiriou,et al.  Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach , 2019, Journal of the National Cancer Institute.

[39]  T. Sørlie,et al.  Re-definition of claudin-low as a breast cancer phenotype , 2019, bioRxiv.

[40]  A. Hida,et al.  Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer , 2019, Breast Cancer Research and Treatment.

[41]  Thomas J. Fuchs,et al.  Clinical-grade computational pathology using weakly supervised deep learning on whole slide images , 2019, Nature Medicine.

[42]  K. Syrigos,et al.  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling , 2019, Clinical Cancer Research.

[43]  L. Pusztai,et al.  Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade , 2019, JCO precision oncology.

[44]  P. Danaher,et al.  Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial , 2019, Journal of Immunotherapy for Cancer.

[45]  Matthew L Albert,et al.  New tools for pathology: a user's review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue , 2019, The Journal of pathology.

[46]  P. Van Loo,et al.  Translating insights into tumor evolution to clinical practice: promises and challenges , 2019, Genome Medicine.

[47]  Shila Ghazanfar,et al.  The human body at cellular resolution: the NIH Human Biomolecular Atlas Program , 2019, Nature.

[48]  Benjamin Haibe-Kains,et al.  Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers , 2019, The Journal of clinical investigation.

[49]  R. Satija,et al.  Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression , 2019, Genome Biology.

[50]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[51]  Jianxin Shi,et al.  Immune gene expression profiling reveals heterogeneity in luminal breast tumors , 2019, Breast Cancer Research.

[52]  M. Mori,et al.  Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk , 2019, JAMA network open.

[53]  Merrick I Ross,et al.  Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.

[54]  Johan Hartman,et al.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.

[55]  Emad A. Rakha,et al.  Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine , 2018, Pathobiology.

[56]  Jack Cuzick,et al.  Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer , 2018, Journal of the National Cancer Institute.

[57]  S. Hirota,et al.  Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers , 2018, Breast Cancer Research and Treatment.

[58]  L. Esserman,et al.  Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer , 2018, Journal of the National Cancer Institute.

[59]  G. Turashvili,et al.  Tumor Heterogeneity in Breast Cancer , 2017, Front. Med..

[60]  K. Al-saleh,et al.  Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. , 2017, Oncology letters.

[61]  N. Artzi,et al.  Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering , 2017, Front. Immunol..

[62]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[63]  S. Loi,et al.  The genomic landscape of breast cancer and its interaction with host immunity. , 2016, Breast.

[64]  M. Cheang,et al.  Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. , 2016, JAMA oncology.

[65]  L. Pusztai,et al.  Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer , 2016, Clinical Cancer Research.

[66]  L. Pusztai,et al.  Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer , 2016, Breast Cancer Research.

[67]  I. Ellis,et al.  Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer , 2016, Breast Cancer Research and Treatment.

[68]  A. Hida,et al.  Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies , 2016, Breast Cancer Research and Treatment.

[69]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[70]  S. Badve,et al.  Tumor Heterogeneity in Breast Cancer , 2015, Advances in anatomic pathology.

[71]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[72]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[73]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[75]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[76]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[78]  V. Band,et al.  Histological, molecular and functional subtypes of breast cancers , 2010, Cancer biology & therapy.

[79]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[80]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[83]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[84]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[85]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2022 , 2022 .

[86]  Yan Liang,et al.  Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironment , 2021, Visualized Cancer Medicine.

[87]  J. Beechem,et al.  GeoMx™ RNA Assay: High Multiplex, Digital, Spatial Analysis of RNA in FFPE Tissue. , 2020, Methods in molecular biology.

[88]  J. Beechem.  High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research. , 2020, Methods in molecular biology.

[89]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[90]  S. Fox,et al.  Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. , 2017, The Lancet. Oncology.

[91]  S. Dudoit,et al.  STATISTICAL METHODS FOR IDENTIFYING DIFFERENTIALLY EXPRESSED GENES IN REPLICATED cDNA MICROARRAY EXPERIMENTS , 2002 .